Ozempic alternatives if you're priced out of the brand

If brand Ozempic costs more than you can pay, there are two kinds of alternative, and they are not the same kind of thing. The first is a cheaper approved product from the same manufacturer. The second is compounded semaglutide, which is a different, unapproved product that contains the same named ingredient. This page takes them in that order, because the first is the one most people miss.

Cheaper approved options from Novo Nordisk

Before anything compounded, check whether a lower-priced approved product fits. Novo Nordisk's own self-pay prices through NovoCare Pharmacy:

• Ozempic pill. Novo lists the Ozempic pill at $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg. Like the pen, it is approved for type 2 diabetes.
• Wegovy pill and pen. Wegovy is semaglutide approved for weight management. Novo sells the Wegovy pill at $149 a month for 1.5 mg (up to $299 at 9 mg and 25 mg), and the pen at $349 a month for its standard doses, with $199 for the first two fills of the starting doses for new patients through December 31, 2026.
• Ozempic pen, self-pay. $349 a month at 0.25 mg to 1 mg and $499 at 2 mg, which is well below what online clinics we track charge for brand Ozempic bundled with a visit. Our guide to getting Ozempic has the full comparison.

Which of these is appropriate is a clinician's decision. The point is that "priced out of Ozempic" often means "priced out of a clinic's bundle," and the manufacturer's own price is lower.

There is no generic Ozempic

No generic version of Ozempic is approved in the US. FDA's Orange Book, the agency's list of approved drug products and their generics, lists every semaglutide product as a Novo Nordisk application and none as a generic, in its September 2026 edition. A product sold as "generic Ozempic" is not an FDA-approved generic.

What compounded semaglutide is

A compounded drug is made by a pharmacy rather than a drug manufacturer, usually for an individual prescription. Compounded semaglutide uses the same named ingredient as Ozempic and Wegovy, but it is a different product:

• It is not FDA-approved. FDA's statement: "Compounded drugs are not FDA-approved. This means the agency does not review their safety, effectiveness or quality before they are marketed." FDA adds that "compounded drugs are also not the same as generic drugs, which are FDA-approved."
• The ingredient form can differ. FDA warns that some compounded semaglutide uses salt forms, and that "these salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs."
• Dosing errors have been reported. FDA says it "received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products," and that these errors "resulted from patients measuring and self-administering incorrect doses of the drug."

So compounded semaglutide is not Ozempic, not a version of Ozempic, and not interchangeable with it.

Where compounded semaglutide stands with FDA

Compounded semaglutide became widespread while brand semaglutide was in shortage. That ended: on February 21, 2025, FDA said it "has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved." It gave state-licensed compounding pharmacies until April 22, 2025, and outsourcing facilities until May 22, 2025, before it would act on compounding that depended on the shortage.

With the shortage over, a pharmacy compounding for individual patients is not supposed to make what FDA calls "essentially copies" of the approved drug, "unless a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient." FDA gives an example of what still counts as a copy: it may consider "a compounded drug product that combines semaglutide API and another API, such as vitamin B12 (cyanocobalamin), to be essentially a copy."

FDA has also gone after how compounded semaglutide is sold. On March 3, 2026, FDA announced "the issuance of 30 warning letters to telehealth companies," citing "claims implying sameness with FDA-approved products." Its consumer warning lists, as a red flag, a company that "makes claims such as the compounded drug is the same as an FDA-approved drug."

What the clinics we track charge for compounded semaglutide

These are the prices on each clinic's own page, re-checked on October 7, 2026, the day this page was published. A compounded semaglutide price is not comparable with a brand Ozempic price, for the reasons above; it is shown here because it is what readers priced out of the brand are being offered. Clinics are listed alphabetically.

Clinic	Compounded semaglutide, as published	Terms
He & She MD	From $99 a month on the annual plan	Annual: $1,188 paid annually; 6-month: $834 every 6 months; 3-month: $447 every 3 months; no month-to-month price shown
Luvo Health	$209 per 4 weeks ($104.50 for the first 4 weeks)	Billed every 28 days, thirteen times a year
MEDGm	$299 billed monthly ($179 for the first month with its coupon)	Longer plans are billed up front, down to $169 a month over 12 months
RxSpan MD	$249 a month; as low as $175 a month on a 12-month plan	The $175 is "billed as one upfront payment of $2,094"; price includes consult, medication, supplies, shipping and support
Synergy Rx	Starting at $199	No unit or commitment stated on the card
Wellorithm	$147 for the first month, then $247	Upfront price; the page does not list what else it covers

Partner disclosure. RxSpan MD, MEDGm and Wellorithm are affiliate partners: we may earn a commission if you sign up through our links. It does not change their prices, their order here, or what we say about them below. Synergy Rx and He & She MD are not partners: their affiliate programs are paused, and we earn nothing from them.

One clinic in the table illustrates the FDA concern above. Synergy Rx's card for its compounded product says "Same active ingredient as Ozempic and Wegovy", and the page never says the product is not FDA-approved. That is the kind of claim FDA has objected to. Under our scoring it caps a clinic's transparency score at 5.0, and we apply that to every clinic, partner or not. Compounded semaglutide is not Ozempic, whatever its card says.